Heterocyclic benzenesulfonylimine derivatives as inhibitors of IL-1 action
AssigneeMerrell Pharmaceuticals Inc.
InventorsGeorge Ku, Boyd L. Harrison, David M. Stemerick
Life of this patent
Estimating the term…
Abstract
The present invention relates to heterocyclic benzenesulfonylimine derivatives and their use as inhibitors of Interleukin-1 (IL-1) action. Such inhibitors are useful in the treatment of various disease states as disclosed herein including rheumatoid arthritis, multiple sclerosis, diabetes mellitus, atherosclerosis, septic shock and pulmonary fibrosis.
Claims12
The method of inhibiting IL-1 action in a patient in need thereof by administering to the patient a therapeutically effective amount of compounds of the structure ##STR6## wherein A is NH, O, or S;
- Q.sub.1 is --OR or --NR.sub.1 R.sub.2 ;
- wherein R, R.sub.1 and R.sub.2 are each independently hydrogen or C.sub.1 -C.sub.6 alkyl radical of branched, straight chained, or cyclic configuration, wherein in the case of a cyclic configuration is C.sub.3 -C.sub.6 cycloalkyl;
- Z is from 1 to 3 substituents chosen independently from the group:
- halogen, C.sub.1 -C.sub.4 alkyl, and C.sub.1 -C.sub.4 alkoxy;
- Y is from 1 to 3 substituents chosen independently from the group:
- C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, and halogen.
A compound of formula ##STR7## wherein A' is O or S;
- Q.sub.2 is --OR.sub.3 or --NR.sub.1 R.sub.2 ;
- wherein R.sub.1, R.sub.2 and R.sub.3 are each independently C.sub.1 -C.sub.6 alkyl radical of branched, straight chained, or cyclic configuration, wherein in the case of a cyclic configuration is C.sub.3 -C.sub.6 cycloalkyl;
- Z is from 1 to 3 substituents chosen independently from the group:
- halogen, C.sub.1 -C.sub.4 alkyl, and C.sub.1 -C.sub.4 alkoxy;
- Y is from 1 to 3 substituents chosen independently from the group:
- C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, and halogen.
Dependencies are inferred from the claim text.